Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal

Fineline Cube Jan 22, 2026
Company Deals

BioRay Pharmaceutical Files HKEX IPO, Backed by First‑in‑Class Autoimmune and Oncology Pipeline

Fineline Cube Jan 22, 2026
Company Deals

BMS Partners with Microsoft on AI‑Powered NSCLC Detection Platform

Fineline Cube Jan 22, 2026
Company Deals

Bayer Partners with Vanderbilt in 5‑Year Deal to Accelerate Cardio‑Renal Drug Discovery

Fineline Cube Jan 22, 2026
Company Deals

Hangzhou Diagens Biotechnology Files HKEX IPO for Medical Imaging AI Platform

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Henlius’s HLX701 Gets NMPA Nod for Phase Ib/II Advanced CRC Combination Study

Fineline Cube Jan 22, 2026
Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Drug

Trinomab Biotech Launches Xintituo for Tetanus Treatment in Zhuhai

Fineline Cube Mar 14, 2025

China-based Trinomab Biotech Co., Ltd announced the first delivery of its antitetanus toxin monoclonal antibody...

Company Drug

Tasly Pharma’s NR-20201 Receives NMPA Approval for Acute Ischemic Stroke Trial

Fineline Cube Mar 14, 2025

China-based Tasly Pharma Co., Ltd (SHA: 600535) announced receiving approval from the National Medical Products...

Company Drug

Jiangsu Aidea’s AD108 Receives NMPA Approval for Acute Ischemic Stroke

Fineline Cube Mar 14, 2025

China’s Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced receiving clinical approval from the National...

Company Deals

Insilico Medicine Closes USD110 Million Series E Round to Advance AI-Driven Drug Pipeline

Fineline Cube Mar 14, 2025

China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine announced the completion of a USD110 million...

Company Deals

Sanyou Medical Raises RMB214 Million for Stake in SMTP Technology

Fineline Cube Mar 14, 2025

China-based Shanghai Sanyou Medical Co., Ltd (SHA: 688085) announced the completion of a private placement...

Company Medical Device

Gaush Meditech Receives NMPA Approval for Femtosecond Laser Corneal Refractive Surgery System

Fineline Cube Mar 14, 2025

Suzhou-based Gaush Meditech Ltd (HKG: 2407) announced receiving market approval from the National Medical Products...

Company

Ipsen Appoints Olivia Brown as Global Head of Neurotoxins, Effective April 1st

Fineline Cube Mar 14, 2025

France-based pharmaceutical company Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced the appointment of Olivia Brown...

Company Drug

China Medical System’s CMS-D003 Receives NMPA Approval for Clinical Study in oHCM

Fineline Cube Mar 14, 2025

China Medical System Holdings (CMS; HKG: 0867) announced receiving approval from the National Medical Products...

Company Drug

Zai Lab Submits TIVDAK BLA to China’s NMPA for Cervical Cancer Treatment

Fineline Cube Mar 14, 2025

Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) announced that a Biological License Application (BLA) for...

Company Drug

Haisco Pharmaceutical’s HSK44459 Receives NMPA Approval for Psoriasis and Atopic Dermatitis Trials

Fineline Cube Mar 14, 2025

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced receiving approval from the National Medical...

Company Medical Device

Johnson & Johnson MedTech Gains FDA Clearance for MONARCH QUEST with AI Algorithms

Fineline Cube Mar 14, 2025

US major Johnson & Johnson MedTech announced receiving U.S. 510(k) regulatory clearance for its MONARCH...

Company Drug

Arvinas and Pfizer Announce Positive Phase III Results for Vepdegestrant in ER+/HER2- Breast Cancer

Fineline Cube Mar 14, 2025

Partners Arvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. (NYSE: PFE) announced positive topline results from...

Company

Harbour BioMed Launches Élancé Therapeutics to Tackle Obesity Treatment Challenges

Fineline Cube Mar 14, 2025

China-based Harbour BioMed (HKG: 2142) announced the establishment of Élancé Therapeutics, a new subsidiary focused...

Company Deals

Pierre Fabre Partners with RedRidge Bio on BPA Drug Development for Oncology and Dermatology

Fineline Cube Mar 14, 2025

France-based Pierre Fabre Laboratories announced an exclusive R&D collaboration and license agreement with Switzerland-headquartered RedRidge...

Company Deals

Visen Pharmaceuticals IPO Launches on Hong Kong Stock Exchange Amid Growth in Endocrine Therapies

Fineline Cube Mar 14, 2025

China-based Visen Pharmaceuticals, a joint venture between Denmark-headquartered Ascendis Pharma and Vivo Capital, has successfully...

Company Deals

Roche and Zealand Pharma Collaborate to Develop Petrelintide for Weight Management

Fineline Cube Mar 14, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced a strategic exclusive collaboration and licensing...

Policy / Regulatory

China Issues Guidelines for Informatization of Compact County-level Medical Communities

Fineline Cube Mar 14, 2025

The National Health Commission (NHC), National Administration of Traditional Chinese Medicine, and National Disease Control...

Drug Policy / Regulatory

CDE Releases 91st Batch of Reference Preparations for Generic Drug Evaluation

Fineline Cube Mar 14, 2025

China’s Center for Drug Evaluation (CDE) has released the 91st batch of reference preparations for...

Medical Device Policy / Regulatory

China’s NHSA Issues Guidelines for Neurological Medical Services Pricing

Fineline Cube Mar 14, 2025

China’s National Healthcare Security Administration (NHSA) has released the “Guidelines for the Pricing Project Initiation...

Company

Grand Pharmaceutical Group Reports Strong 2024 Financials with 12.8% Revenue Growth

Fineline Cube Mar 14, 2025

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) revealed its 2024 financial performance, recording revenues...

Posts pagination

1 … 143 144 145 … 612

Recent updates

  • Ascletis Selects ASC37 as Clinical Candidate for Monthly Triple Agonist Therapy
  • Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal
  • Henlius’s HLX701 Gets NMPA Nod for Phase Ib/II Advanced CRC Combination Study
  • BioRay Pharmaceutical Files HKEX IPO, Backed by First‑in‑Class Autoimmune and Oncology Pipeline
  • BMS Partners with Microsoft on AI‑Powered NSCLC Detection Platform
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company R&D

Ascletis Selects ASC37 as Clinical Candidate for Monthly Triple Agonist Therapy

Company Deals

Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal

Company Drug

Henlius’s HLX701 Gets NMPA Nod for Phase Ib/II Advanced CRC Combination Study

Company Deals

BioRay Pharmaceutical Files HKEX IPO, Backed by First‑in‑Class Autoimmune and Oncology Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.